CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation

BACKGROUND/AIM: High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy for multiple myeloma (MM) patients who are eligible for it. The recommended dose of CD34+ hematopoietic progenitor cells (HPCs) for adequate engraftment is above 2 ×...

Descripción completa

Detalles Bibliográficos
Autores principales: ALADAĞ, Elifcan, DEMİROĞLU, Haluk, BÜYÜKAŞIK, Yahya, TURGUT, Mehmet, AKSU, Salih, SAYINALP, Nilgün, HAZNEDAROĞLU, İbrahim Celalettin, ÖZCEBE, Osman İlhami, GÖKER, Hakan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775700/
https://www.ncbi.nlm.nih.gov/pubmed/32512672
http://dx.doi.org/10.3906/sag-2001-173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775700/
https://www.ncbi.nlm.nih.gov/pubmed/32512672
http://dx.doi.org/10.3906/sag-2001-173

Ejemplares similares